Small-Cap Stock on Watch: Cell Therapeutics Inc. (CTIC)
  • Stock Report for FiberTower Corp. (FTWR)
  • Stock Report for Fannie Mae (FNMA)
  • " />

    Stock Report for Cell Therapeutics Inc. (CTIC)

    Cell Therapeutics Inc. (CTIC) engages in the development, acquisition and commercialization of treatments for cancer. The Company focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs. Its research, development, acquisition and in-licensing activities concentrate on identifying and developing less toxic ways to treat cancer. CTIC is focused on Pixuvri (pixantrone dimaleate), OPAXIO (paclitaxel poliglumex), or OPAXIO, brostallicin and bisplatinates. It is developing a dinuclear-platinum complex. There are three platinates commercially available (cisplatin, carboplatin, and oxaliplatin), which are first-line agents in ovarian cancer, lung cancer, testicular cancer, and colorectal cancer, as well as a range of other diseases. CTIC is developing the dinuclear-platinum complex CT-47463, which has a different mechanism of action than the platinum compounds.

    Share Statistics (17-Feb-12)   FY












    Symbol CTIC Revenue, $Mn 0.08 0.32 300.0% 0.00 0.00 0.0%
    Current price $1.35 Gross marg. 100.0% 100.0% 0.0%
    52wk Range: $0.95-$3.30 Oper. margin -23479.6%  
    Avg Vol (3m): 2,042,430 Net margin -119237.5% -25825.0% -78.%
    Market Cap. 249.74M              
    Shares Outstanding 185.00M EPS, $ -1.55 -1.29 -16.8% -0.13 -0.16 23.1%

    Source:, SEC Filings.

    Investment Highlights

    Shares of  drug maker Cell Therapeutics Inc. (CTIC) leaped 21.62% to close at $1.35  Friday, boosted by news the Company has gained conditional approval for Pixuvri from the European Medicines Agency (EMA).

    Shares of the Seattle-based company have gained 25.0% in the last five days; 21.6% in the last month; and 12.5% in the six months to date.

    According to the release, CTIC’s cancer drug Pixuvri has been granted a positive opinion for conditional approval from the EMA’s Committee for Medicinal Products for Human Use (CHMP). Based on the CHMP’s recommendation, CTIC expects that a conditional marketing authorization for Pixuvri should be granted by the European Commission within the next few months. CHMP recommended Pixuvri for conditional approval as monotherapy for the treatment of adult patients with multiple relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL).

    If the CHMP’s recommendation is formally adopted by the European Commission, Pixuvri would be approved for marketing in the 27 countries that are members of the E.U., as well as the European Economic Area. The decision by the European Commission is typically issued approximately two to three months after the CHMP opinion and generally follows the recommendation from the CHMP. If the opinion is confirmed by the European Commission, Pixuvri would be the first drug approved for patients in this setting.

    James A. Bianco, CEO of CTIC, commented: “We are very pleased with the CHMP’s positive recommendation recognizing the clinical benefit of Pixuvri in addressing a significant unmet medical need for patients with multiple relapsed or refractory aggressive B-cell NHL, and we believe that Pixuvri will add an important treatment option for physicians and provide a meaningful impact on patients.”

    CTIC saw its shares plunge in late January after announcing that it has withdrawn its approval application for Pixuvri in the U.S. The Company said the application was withdrawn because it needed additional time to prepare for the review of the Pixuvri New Drug Application (NDA) by the FDA’s Oncologic Drugs Advisory Committee (ODAC) at its February 9, 2012 meeting.

    The Company plans to resubmit the NDA later this year.


    Financial Summary

    CTIC reported net loss attributable to common shareholders of $29.7 million, or $0.16 per share, for the quarter ended September 30, 2011, compared to a net loss attributable to common shareholders of $15.6 million, $0.13 per share, for the same period in 2010. The Company primarily attributed the increase in net loss to $13.0 million in non-cash deemed dividends on preferred stock issuances and a $2.4 million increase in research and development expenses primarily associated with the pixantrone PIX306 clinical study.  Total operating expenses for the third quarter were $15.3 million, compared to $13.0 million for the same period in 2010.

    For the nine months ended September 30, 2011, CTIC realized a net loss attributable to common shareholders of $103.2 million, $0.62 per share, down from $113.4 million, $1.03 per share, reported for the comparable period of 2010. The Company attributed the lower net loss to a drop in selling, general and administrative expenses. Total operating expenses declined to $52.3 million, which included a one-time upfront payment of $5.0 million related to the licensing of tosedostat from Chroma Therapeutics Ltd., compared to $58.8 million for the same period in 2010.

    The Company had about $45.2 million in cash and cash equivalents as of September 30, 2011, which does not include approximately $8.2 million in other proceeds received in October 2011 in connection with the settlement of a lawsuit.


    Financial Strength (17-Feb-12)




    S&P 500

    Quick Ratio (MRQ) 3.09 1.42 0.58
    Current Ratio (MRQ) 1.62 3.91 1.76 0.93
    LT Debt to Equity (MRQ) 19.16 23.05 24.54 171.20
    Total Debt to Equity (MRQ) 104.91 26.29 33.74 228.68
    Interest Coverage (TTM) -22.22 51.46 2.49 27.43

    Source:, SEC Filings.

    Technical Analysis


    CTIC is within its Bollinger Bands. This is a normal condition suggesting that it is neither overbought nor oversold relative to the recent levels.

    CTIC’s MACD is currently indicating a weak bullish signal. Although the MACD is trending above the signal line, the indicator is still below 0, which suggests that the underlying moving averages are bearish.

    Comparative Analysis

    Company Name Ticker Price per Mrkt. Cap. P/E P/S
    Feb17-2012 symbol Share, $ $ Mn 2011 2012 2011 2012
    Roche Holding AG RHHBY 44.10 149.50B 12.25 11.16 3.23 3.09
    Sanofi SNY 37.16 98.90B 7.65 6.10 2.15 2.09
    Bristol-Myers Squibb Co. BMY 33.13 56.11B 16.82 17.08 3.11 3.31
    Biotechnology Median       17.39 n/a 9.12 n/a
    Cell Therapeutics Inc. CTIC 1.35 253.44M n/a n/a n/a 4.36

    Source: Thomson Financial

    DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

    The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

    Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

    Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

    Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

    We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

    To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

    We encourage you to invest carefully and read investment information available at the websites of the SEC at and FINRA at

    Leave a Reply

    Your email address will not be published. Required fields are marked *